On Christmas night, my husband—the CEO—issued an ultimatum: “Apologize to my new girlfriend, or lose your salary and any chance of promotion.” I said only one word: “Fine.” The next morning, my luggage was packed, and my transfer to London had already been finalized

“Yes,” I said. “While you underestimated me.”

That night, I boarded a flight alone.

New York was cold and unfamiliar—but honest. The team welcomed clarity. Trust was rebuilt. Funding returned to meaningful research. Progress followed, slowly but steadily.

Back home, things unraveled.

Daniel and Lauren doubled down on cosmetics, gutting long-term research for short-term gains. Senior scientists resigned. Trials failed. Regulators took notice. The company’s reputation fractured.

William visited me once. Over coffee, he said quietly, “You reminded me what this company was meant to be.”

For the first time in years, I slept without dread.

Eighteen months later, the New York division became the most stable and ethically respected arm of Harrington Biotech. Rare-disease trials advanced. Talent returned for purpose, not prestige.

Meanwhile, headquarters bled quietly.

The ethics investigation confirmed everything: misuse of funds, conflicts of interest, systemic pressure. Regulators intervened.

Daniel resigned before he could be removed.
Lauren left soon after—no announcement, no farewell.

William later amended his estate.
“Forty percent voting power,” he told me. “And the option to return as CEO.”